Immunotherapy combo shows promise in tough prostate cancer
NCT ID NCT04717154
First seen Jan 07, 2026 · Last updated May 10, 2026 · Updated 19 times
Summary
This study tested a combination of two immunotherapy drugs (ipilimumab and nivolumab) in 69 men with a specific type of advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the treatment could shrink tumors or stop the cancer from growing for at least 6 months. Participants received 4 cycles of the drug combination, followed by nivolumab alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Radboudumc
Nijmegen, Gelderland, 6525GA, Netherlands
Conditions
Explore the condition pages connected to this study.